19th Pharmacovigilance 2019

From Verify.Wiki
Jump to: navigation, search
Wizard photo 19th Pharmacovigilance 2019 1.jpg
19th Pharmacovigilance 2019
Date 2019-10-08
Place 08th – 10th Oct 2019,
Double Tree Suites by Hilton Hotel

400 Soldiers Field Road, Boston, MA 02134

19th Pharmacovigilance 2019 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting Pv development. What does the future hold for pv? Find out at our conference on opportunities and activities shaping pv to 2020 with respect to regulations, technologies and services. Learn and know on what are drug producers and service providers doing? What regulations and technologies influence the current PV field? You can also discover at 19th Pharmacovigilance 2019 on spending forecasts for PV (US, the EU and Asia).


Top Photos

Top Videos

KEY SPEAKERS

·         DEREK ROY, Resident Agent in Charge, FDA

·         BRUNO MENDEZ, VP Global Quality Head Pharmacovigilance, Sanofi

·         MARIETTE BOERSTOEL-STREEFLAND, Sr. VP PharmacoVigilance & Drug Safety, Alexion Pharmaceuticals

·         COLLEEN WALSH, Senior Director, Pharmacovigilance & Regulatory Quality Management Operations, Alexion Pharmaceuticals

·         GERSON PELTZ, Senior Director - Oncology Safety Risk Lead, Pfizer

·         SANDRA RAFF, Senior Director, Global Drug Safety and Risk Management, Takeda Pharmaceuticals

·         BRUCE DONZANTI, Senior Group Director, Regulatory Pharmacovigilance Policy, Genentech

·         WILLIAM WANG, Executive Director, Clinical Safety Statistics, Merck

·         MELVIN MUNSAKA, Senior Director, Head Safety Statistics, Abbvie

·         XIAO NI, Director, Scientific Computing and Consulting, Novartis

·         SHARON REID, Director, Risk Management Product Lead, Pfizer

·         WILLIAM BLUMENTALS, Sr. Director, Head of Pharmacoepidemiology, Sanofi Genzyme

·         ANNAYA BHATTACHARYA, Global Lead for Safety & Risk Management, Bristol-Myers Squibb

·         HARISHA KADALI, Associate Medical Director, Takeda Pharmaceuticals

·         JAYLAXMI NALAWADE, Associate Director - Pharmacovigilance and REMS, Lupin

·         RICHARD WOLF, Executive Director, Pv Operations, CSL Behring

·         PHIL TREGUNNO, Group Manager - Vigilance, Intelligence and Research Group, MHRA (UK)

·         STEINAR MADSEN, Medical Director, Norwegian Medicines Agency (UK)

·         HEATHER LEIGH FLANNERY, Global Lead, ConsenSys Health

·         TOYIN ADEWOLE, Associate Director, Drug Safety - Clinical Research, Supernus Pharmaceuticals

·         SANJEEV MIGLANI, Founder and Director, AWINSA Life Sciences

·         MUGDHA CHOPRA, Cofounder & Director, AWINSA Life Sciences

·         KEVIN TYNAN, Consultant, Global Clinical Safety and Pharmacovigilance, CSL Behring

·         ISRAEL GUTIERREZ, VP Pharmacovigilance & Drug Safety, Geron Corporation

·         SHEETAL KHEDAR, Senior Director, Regulatory Science, Sarah Cannon Development Innovations

·         DAVID HUTCHINSON, Founder, Brookwood International Academy

·         MELVA COVINGTON, Senior Principal, AGAPE Strategic Solutions

·         BEN LOCWIN, Senior Vice President, Quality, Lumicell

Plus more joining soon

KEY THEMES

·         Pharmacovigilance in the US: What comes next for the industry?

·         Recent developments - legislation, policies, systems, technology, communication strategies and best practice in PV

·         Challenges and Opportunities for Effective Pharmacovigilance in the 21st Century

·         Why does pharmacovigilance sometimes fail and where
could the fault lie?

·         Pharmacovigilance and healthcare system

·         Future of Signal Detection - Growing companies and safety efficiencies

·         Technology Impact - Cloud – Big data – Analytics – AI – Machine learning

·         Good Clinical Practices and Good Pharmacovigilance practices

·         Future of outsourced phase I, II and III trials and post-marketing studies,

·         Data quality management and analysis – analyzing the new guidelines

·         Strategies to improve clinical trials and PV

·         Maintaining proper balance in relationships: Sponsor – Site – CRO & Patients

·         Patient centric approach to help improve patient safety

·         Outsourcing activities - Choosing your right vendor and setting the path right

·         PV Audit & inspections - preparation, implementation and lessons to be learnt

·         Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models

·         Current regulations and guidelines - USA, EU and RoW

·         The developing regulatory framework in advanced and developing markets

·         Be part of a major networking opportunity

WHO SHOULD ATTEND

CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing

CONFERENCE REGISTRATION

In order to please register contact us on Email: kavitha@virtueinsight.co.in  Tel: +44 2036120886

Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event.

Conference Only:

·         Introductory Offer (3 delegate places for the price of 2) A huge saving  (Limited seats left)

·         Early Discount (25th June 2019 - 19th August 2019): (£1299 per delegate)

·         Standard Registration (20th August 2019 Onwards): (£1499 per delegate)

Conference + Workshop:

·         Introductory Offer (3 delegate places for the price of 2) A huge saving - (Limited seats left)

·         Early Discount (25th June 2019 - 19th August 201): (£1499 per delegate)

·         Standard Registration (20th August 2019 Onwards): (£1699 per delegate)

Verification history

  • This page has not been verified